Bioaerosol Sampling in Suspected Pulmonary Tuberculosis
Study Details
Study Description
Brief Summary
Tuberculosis (TB) is transmitted in bioaerosols containing Mycobacterium tuberculosis (Mtb). Mtb-containing bioaerosols are likely related to host infectiousness and central to ongoing TB transmission. No routine diagnostic assay exists to measure Mtb in bioaerosols. Furthermore, published studies of Mtb in bioaerosol samples, have been limited to individuals with sputum-positive pulmonary TB. Currently TB diagnosis is based on clinical symptoms and sputum laboratory findings. However, approximately half of all patients commencing TB treatment are sputum negative resulting in a high proportion of presumptive treatments. We therefore propose to use a sensitive sampling protocol to investigate the prevalence of Mtb-containing bioaerosols in both sputum-positive and sputum-negative TB suspects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Our pragmatic, parallel-group design is aimed at identifying viable Mtb in bioaerosols produced by individuals attending a TB clinic in Cape Town, South Africa. Bioaerosol sampling will be performed on all eligible individuals presenting with symptoms indicative of TB and repeated at 14 days if initially positive for viable Mtb. Participants will be classified into three distinct groups based on the National TB Control Program (NTBCP) criteria: Group A, TB notification with sputum-based laboratory confirmation; Group B, TB notification with empiric diagnosis; and Group C, individuals not notified. Group C individuals with detectable Mtb bioaerosol will be monitored until resolution of clinical and laboratory status. Collection of bioaerosol specimens will be via two consecutive sampling modalities: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect sampling following passive respiratory activity and environmental sampling. microscopy. Mtb genomes and mycobacterial and host lipids will be detected using droplet digital PCR and mass spectrometry analyses, respectively. The primary objective is to determine the prevalence of Mtb bioaerosols in all TB clinic attendees and in each of the mutually exclusive groups A, B and C. Secondary objectives are to investigate differences in prevalence of Mtb bioaerosol by HIV status, current isoniazid preventive therapy (IPT) use and pre and post initiation of anti-TB chemotherapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| A: Notified TB with sputum laboratory confirmation Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days. |
Diagnostic Test: Bioaerosol Sampling
Cyclone collection of exhaled bioaerosol
|
| B: Notified TB without sputum laboratory confirmation Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days. |
Diagnostic Test: Bioaerosol Sampling
Cyclone collection of exhaled bioaerosol
|
| C: Not Notified for TB Bioaerosol Sampling: (1) direct sampling of a specific respiratory manoeuvre; and (2) indirect, following passive respiratory activity and environmental sampling. Repeat bioaerosol sampling will be conducted at 14 days. |
Diagnostic Test: Bioaerosol Sampling
Cyclone collection of exhaled bioaerosol
|
Outcome Measures
Primary Outcome Measures
- Primary Aim [12 months]
The difference in prevalence proportions of Mtb-containing bioaerosol in sputum positive and sputum negative pulmonary TB cases (Groups A & B)
Secondary Outcome Measures
- Secondary Aim (1) [12 months]
The difference in numbers of viable MTB organisms in bioaerosols per liter of air sampled and per nano-liter of bioaerosol particulate volume collected in both sputum positive and sputum negative pulmonary TB cases (Groups A & B).
Other Outcome Measures
- Exploratory Aim (1) [12 months]
The prevalence of MTB containing bioaerosols in TB suspects not diagnosed with clinical TB (Group C)
- Exploratory Aim (2) [12 months]
The difference in prevalence and numbers of viable MTB in subjects receiving and not receiving IPT prophylaxis.
- Exploratory Aim (3) [12 months]
The difference in prevalence and numbers of viable MTB in subjects with and without HIV-infection.
- Exploratory Aim (4) [12 months]
The difference in prevalence and numbers of viable MTB in subjects before and after TB therapy.
- Exploratory Aim (5) [12 months]
The difference in numbers of viable MTB in bioaerosol collected by direct and indirect sampling.
- Exploratory Aim (6) [12 months]
The ratio of MTB genomes (ddPCR) to viable MTB organisms (DMN-tre-positive) in MTB containing bioaerosol
- Exploratory Aim (7) [12 months]
Which MTB lipids are present in MTB containing bioaerosol
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age over 13 years
-
person with suspected TB
-
provision of written, informed consent (parental consent and patient assent for those aged under 18yrs)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aerobiology Research Centre | Cape Town | Western Cape | South Africa |
Sponsors and Collaborators
- Desmond Tutu HIV Foundation
- Zeteo Tech LLC
- National Institutes of Health (NIH)
- Institute of Infectious Disease, University of Cape Town
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- R01AI147347-01